Pharmaceutical

BioDelivery Sciences International (NASDAQ:BDSI) and Purdue Pharma announced today that BELBUCA® (buprenorphine) buccal film is now commercially available in Canada. As quoted in the press release: “It is important for us to work with an organization that has a strong commitment to pain management in Canada, such as Purdue Pharma (Canada), and we are very …

BioDelivery Sciences International (NASDAQ:BDSI) and Purdue Pharma announced today that BELBUCA® (buprenorphine) buccal film is now commercially available in Canada.
As quoted in the press release:

“It is important for us to work with an organization that has a strong commitment to pain management in Canada, such as Purdue Pharma (Canada), and we are very pleased that BELBUCA is now available to Canadian patients managing chronic pain,” said Scott Plesha, President of BioDelivery Sciences

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20532.18+148.43
TSXV714.66+12.92
DOW32637.19+516.91
S&P 5004057.84+79.11
NASD11740.65+305.91
ASX7105.90-49.30

COMMODITIES

Commodities
Gold1854.09+1.02
Silver22.09+0.07
Copper4.30+0.04
Palladium2029.53+21.52
Platinum954.50+5.50
Oil114.19+0.10
Heating Oil3.850.00
Natural Gas8.83-0.07

DOWNLOAD FREE REPORTS

×